Heron Therapeutics (HRTX) Raw Materials (2016 - 2026)

Heron Therapeutics has reported Raw Materials for 11 years, with the latest figure at $60.6 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials rose 210.43% year-over-year to $60.6 million; the trailing twelve-month figure through Mar 2026 stood at $60.6 million (up 210.43% YoY), and the FY2025 full-year result was $59.2 million, up 200.26% from the prior year.
• Raw Materials for Q1 2026 stood at $60.6 million, up from $59.2 million in the prior quarter.
• The five-year high for Raw Materials was $60.6 million in Q1 2026, with the low at $15.1 million in Q4 2022.
• Historically, Raw Materials has averaged $25.6 million across 5 years, with a median of $19.6 million in 2024.
• Annual changes were most pronounced in 2023 — Raw Materials slumped 36.02% — and 2026, when it soared 210.43%.
• Heron Therapeutics' Raw Materials stood at $15.1 million in 2022, then advanced by 16.56% to $17.6 million in 2023, then increased by 11.85% to $19.7 million in 2024, then soared by 200.26% to $59.2 million in 2025, then advanced by 2.21% to $60.6 million in 2026.
• The last three Raw Materials figures came in at $60.6 million (Q1 2026), $59.2 million (Q4 2025), and $32.8 million (Q3 2025), per Business Quant data.